Drug Pricing
Blog
The FTC Is Settling for Lower Drug Prices
The FTC alleged that Express Scripts “artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients.” This is a big win – and not just for ...
Commentary
The Real Profiteers in Healthcare Aren’t Drugmakers
Pressure is building on Capitol Hill for Congress to codify President Trump’s “most favored nation” drug-pricing initiative into law. The administration has already struck deals with more than a dozen drugmakers to sell medicines to Medicaid, the federal-state health plan for low-income individuals and the disabled, at the lowest prices ...
Commentary
Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire
President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Commentary
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
Commentary
In the rush to hold insurers to account, don’t forget about hospitals
When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
Commentary
Open, Competitive Market Will Make Trump’s Health Plan Great
President Trump’s recently released Great Healthcare Plan offers several welcome reforms. It endeavors to put patients first by fostering greater price transparency and taking steps to lower health insurance premiums. Its approach to prescription drug policy is a bit more mixed. Read the op-ed here.
Commentary
CMS Officials Are Undermining Trump’s Push For Affordable Drugs
Officials at the Centers for Medicare and Medicaid Services just undermined President Trump’s efforts to make prescription drugs more affordable. Earlier this week, CMS announced the next 15 medicines that will face price caps under Medicare’s Drug Price “Negotiation” Program, a core component of the Inflation Reduction Act signed into ...
Drug Prices
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
SACRAMENTO – California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal government’s new prescription drug pricing program enacted under the Inflation Reduction Act. The cases, Janssen Pharmaceuticals, Inc. ...
Commentary
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
Blog
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
The FTC Is Settling for Lower Drug Prices
The FTC alleged that Express Scripts “artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients.” This is a big win – and not just for ...
The Real Profiteers in Healthcare Aren’t Drugmakers
Pressure is building on Capitol Hill for Congress to codify President Trump’s “most favored nation” drug-pricing initiative into law. The administration has already struck deals with more than a dozen drugmakers to sell medicines to Medicaid, the federal-state health plan for low-income individuals and the disabled, at the lowest prices ...
Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire
President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
In the rush to hold insurers to account, don’t forget about hospitals
When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
Open, Competitive Market Will Make Trump’s Health Plan Great
President Trump’s recently released Great Healthcare Plan offers several welcome reforms. It endeavors to put patients first by fostering greater price transparency and taking steps to lower health insurance premiums. Its approach to prescription drug policy is a bit more mixed. Read the op-ed here.
CMS Officials Are Undermining Trump’s Push For Affordable Drugs
Officials at the Centers for Medicare and Medicaid Services just undermined President Trump’s efforts to make prescription drugs more affordable. Earlier this week, CMS announced the next 15 medicines that will face price caps under Medicare’s Drug Price “Negotiation” Program, a core component of the Inflation Reduction Act signed into ...
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
SACRAMENTO – California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal government’s new prescription drug pricing program enacted under the Inflation Reduction Act. The cases, Janssen Pharmaceuticals, Inc. ...
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...